{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:08:03Z","timestamp":1790356083477,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03173-1","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:01:18Z","timestamp":1787331678000},"page":"2095-2101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (second edition)\u2014breast cancer"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-7683","authenticated-orcid":false,"given":"Yuko","family":"Takano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taijiro","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Koi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Tokuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the JSMO\/JSCO Clinical Practice Guideline Committee for Pharmacotherapy in Older Adults with Cancer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"3173_CR1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2","journal-title":"Lancet"},{"key":"3173_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273\u20131283. https:\/\/doi.org\/10.1056\/NEJMoa0910383","journal-title":"N Engl J Med"},{"key":"3173_CR3","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","volume":"32","author":"EA Perez","year":"2014","unstructured":"Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744\u20133752. https:\/\/doi.org\/10.1200\/JCO.2014.55.5730","journal-title":"J Clin Oncol"},{"key":"3173_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134\u2013141. https:\/\/doi.org\/10.1056\/NEJMoa1406281","journal-title":"N Engl J Med"},{"key":"3173_CR5","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684. https:\/\/doi.org\/10.1056\/NEJMoa052122","journal-title":"N Engl J Med"},{"key":"3173_CR6","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1200\/JCO.20.00184","volume":"38","author":"M Sawaki","year":"2020","unstructured":"Sawaki M, Taira N, Uemura Y et al (2020) Randomized controlled trial of trastuzumab with or without chemotherapy for HER2-positive early breast cancer in older patients. J Clin Oncol 38:3743\u20133752. https:\/\/doi.org\/10.1200\/JCO.20.00184","journal-title":"J Clin Oncol"},{"key":"3173_CR7","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.20.01204","volume":"39","author":"M Piccart","year":"2021","unstructured":"Piccart M, Procter M, Fumagalli D et al (2021) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years\u2019 follow-up. J Clin Oncol 39:1448\u20131457. https:\/\/doi.org\/10.1200\/JCO.20.01204","journal-title":"J Clin Oncol"},{"key":"3173_CR8","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R et al (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 386:556\u2013567. https:\/\/doi.org\/10.1056\/NEJMoa2112651","journal-title":"N Engl J Med"},{"key":"3173_CR9","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH et al (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396:1090\u20131100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31953-X","journal-title":"Lancet"},{"key":"3173_CR10","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/jnci\/djae129","volume":"116","author":"R Dent","year":"2024","unstructured":"Dent R, Cort\u00e9s J, Pusztai L et al (2024) Neoadjuvant pembrolizumab plus chemotherapy\/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. J Natl Cancer Inst 116:1654\u20131663. https:\/\/doi.org\/10.1093\/jnci\/djae129","journal-title":"J Natl Cancer Inst"},{"key":"3173_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41523-022-00457-3","volume":"8","author":"CH Barrios","year":"2022","unstructured":"Barrios CH, Saji S, Harbeck N et al (2022) Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer. npj Breast Cancer 8:108. https:\/\/doi.org\/10.1038\/s41523-022-00457-3","journal-title":"npj Breast Cancer"},{"key":"3173_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J et al (2023) Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 24:77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(22)00694-5","journal-title":"Lancet Oncol"},{"key":"3173_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S1470-2045(20)30534-9","volume":"22","author":"M Toi","year":"2021","unstructured":"Toi M, Imoto S, Ishida T et al (2021) Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22:74\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(20)30534-9","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03173-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:50:34Z","timestamp":1790355034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03173-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3173"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03173-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"3 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"YT reports institutional research funding from Eli Lilly Japan K.K. for a sponsored clinical trial for which YT served as the principal investigator. YT received honoraria for lectures from Eli Lilly Japan K.K.; Daiichi Sankyo Co., Ltd.; Pfizer Japan Inc.; Chugai Pharmaceutical Co., Ltd.; MSD K.K.; and Gilead Sciences K.K. AS received grants from Daiichi-Sankyo, Gilead Sciences, Pfizer, and MSD outside the submitted work. AS received personal fees from Eli-Lilly Japan, Daiichi-Sankyo, MSD, and AstraZeneca outside the submitted work, and received honoraria for lectures from Eli Lilly Japan K.K., MSD K.K., Chugai Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. FN reports grants from Taiho Pharmaceutical, Ono Pharmaceutical, Oncotherapy, Merck Serono, Zeria Pharmaceutical, Lilly Japan, Takeda Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Sumitomo Dainippon Pharma, Daiichi Sankyo, Shionogi, J-Pharma, Bristol-Myers Squibb, Kyowa Kirin, Mochida Pharmaceutical, Astellas Pharma, Bayer, MSD, Eisai, NanoCarrier, Janssen, Baxalta\/Shire, and Novartis; and honoraria from Taiho Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Chugai Pharmaceutical, Yakult Honsha, Janssen, Merck Biopharma, and Daiichi Sankyo. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}